An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Public ClinicalTrials.gov record NCT01064414. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment
Study identification
- NCT ID
- NCT01064414
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Enrollment
- 272 participants
Conditions and interventions
Conditions
Interventions
- Canagliflozin Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 25 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2010
- Primary completion
- Nov 30, 2011
- Completion
- Jul 31, 2012
- Last update posted
- Aug 13, 2013
2010 – 2012
United States locations
- U.S. sites
- 26
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Concord | California | — | — |
| Not listed | Fountain Valley | California | — | — |
| Not listed | San Diego | California | — | — |
| Not listed | Denver | Colorado | — | — |
| Not listed | Pembroke Pines | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | West Palm Beach | Florida | — | — |
| Not listed | Augusta | Georgia | — | — |
| Not listed | Nampa | Idaho | — | — |
| Not listed | Baton Rouge | Louisiana | — | — |
| Not listed | Jackson | Mississippi | — | — |
| Not listed | Picayune | Mississippi | — | — |
| Not listed | Chesterfield | Missouri | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Albuquerque | New Mexico | — | — |
| Not listed | Durham | North Carolina | — | — |
| Not listed | Canal Fulton | Ohio | — | — |
| Not listed | Cincinnati | Ohio | — | — |
| Not listed | Columbus | Ohio | — | — |
| Not listed | Zanesville | Ohio | — | — |
| Not listed | Oklahoma City | Oklahoma | — | — |
| Not listed | Meridian | Pennsylvania | — | — |
| Not listed | Pittsburgh | Pennsylvania | — | — |
| Not listed | North Charleston | South Carolina | — | — |
| Not listed | Salt Lake City | Utah | — | — |
| Not listed | Fairfax | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 80 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01064414, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2013 · Synced Jun 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01064414 live on ClinicalTrials.gov.